


SCOPE OF THE CLAIM

- 50-5
A2
1. Substituted benzylthiazolidine-2,4-dione derivatives represented by a general formula (1)




[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates.

2. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein A is phenyl group which is unsubstituted or may have substituents.
3. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein A is phenoxy group which is unsubstituted or may have substituents.
4. The substituted benzylthiazolidine-2,4-dione derivatives, their medicinally acceptable salts and their hydrates of Claim 1, wherein A is benzyloxy group which is unsubstituted or may have substituents.
5. A compound of Claim 1, being N-[(4-benzyloxyphenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

6. A compound of Claim 1, being N-[(4-phenoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.


7. A compound of Claim 1, being N-[(biphenyl-4-yl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, its medicinally acceptable salts and its hydrates.

8. A blood glucose-decreasing drug having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates as effective ingredients.


9. A lipid in blood-decreasing drug having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is

unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates as effective ingredients.

10. An agonistic drug of human peroxisome proliferator-activated receptor having at least one or more kinds of substituted benzylthiazolidine-2,4-dione derivatives represented by the general formula (1)



[wherein A denotes a phenyl group which is unsubstituted or may have substituents, phenoxy group which is unsubstituted or may have substituents or benzyloxy group which is unsubstituted or may have substituents], their medicinally acceptable salts and their hydrates as effective ingredients.

add

A2